3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans.

@article{Segura200134DihydroxymethamphetamineA,
  title={3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans.},
  author={Mireia Segura and Jordi Ortu{\~n}o and Magı́ Farr{\'e} and J Mclure and Mitona Pujadas and Nieves Pizarro and Antoine Llebaria and Jes{\'u}s Joglar and Pere Nolasc Roset and Jordi Segura and Rafael de la Torre},
  journal={Chemical research in toxicology},
  year={2001},
  volume={14 9},
  pages={1203-8}
}
There is evidence that some heavy users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) show signs of neurotoxicity (a cognitive dysfunction, a larger incidence of psychopathology). It has been postulated that the catechol intermediates of methylenedioxyamphetamines such as 3,4-dihydroxymethamphetamine (HHMA), a metabolite of MDMA, may play a role in their neurotoxicity by formation of thioether adducts. This study describes the first validated method for HHMA determination in plasma and… CONTINUE READING
Highly Influential
This paper has highly influenced 10 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS